Gain Therapeutics

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Presented Additional Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Utility in Parkinson's Disease and Gaucher Disease Presented Additional Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Utility in Parkinson's Disease and Gaucher Disease

Gain Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Business Update

Gain Therapeutics, Inc. (GANX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gain Therapeutics, Inc. (GANX) Expected to Beat Earnings Estimates: Should You Buy?

BETHESDA, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that the company's Chief Operating Officer, Matthias Alder, will present and host one-on-one meetings at the Jefferies Healthcare Conference taking place June 8-10 in New York, NY. Please see additional details below:

Gain Therapeutics to Participate at the Jefferies Healthcare Conference

BETHESDA, Md., May 18, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that the company's Chief Executive Officer, Eric Richman, will present and host one-on-one meetings at the H.C. Wainwright Global Investment Conference taking place May 23-25 in Miami, Florida. Please see additional details below:

Gain Therapeutics to Participate at the H.C. Wainwright Global Investment Conference

Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.65% and 25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Misses Revenue Estimates

Presented Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Study in Parkinson's Disease and Gaucher's Disease.

Gain Therapeutics, Inc. Reports First Quarter 2022 Financial Results and Business Update

Lead compound GT-02329 increases GCase levels and activity, depletes toxic substrates glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph) in relevant Gaucher disease (GD) models Lead compound GT-02329 increases GCase levels and activity, depletes toxic substrates glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph) in relevant Gaucher disease (GD) models

Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium

Lead Compound GT-02287 is Brain Penetrant, Reduces Alpha-synuclein, and Increases Dopamine in Relevant Neuronal Models Lead Compound GT-02287 is Brain Penetrant, Reduces Alpha-synuclein, and Increases Dopamine in Relevant Neuronal Models

Gain Therapeutics Presents Positive Preclinical Data on its Small Molecule Lead Compound in GBA1 Parkinson's Disease at XXVII IAPRD World Congress

Gain Therapeutics, Inc. (GANX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

BETHESDA, Md., April 26, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform, today announced that Chief Executive Officer Eric Richman will participate in a fireside chat during the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference, and invites investors to participate via webcast. Please see additional details below:

Gain Therapeutics to Participate in the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

Gain Therapeutics Inc (NASDAQ: GANX) has presented new preclinical data from its Parkinson's Disease (PD) program at the 2022 Synuclein Meeting.  The data show that the lead compound GT-02287 increases the levels and activity of the beta-glucocerebrosidase (GCase) protein,.

Gain Therapeutics Shares Skyrocket After Preclinical Data From Parkinson's Program

Lead candidate GT-02287 is bioavailable, increases GCase levels, depletes alpha-synuclein, increases lysosomal health, and improves neuronal network and survival in relevant neuronal cell models Lead candidate GT-02287 is bioavailable, increases GCase levels, depletes alpha-synuclein, increases lysosomal health, and improves neuronal network and survival in relevant neuronal cell models

Gain Therapeutics Presents Positive Data on its Small Molecule Lead Compound in GBA1 Parkinson's Disease at the 2022 Synuclein Meeting

Study results demonstrate lead compounds increase GCase protein levels, activity and co-localization in the lysosome, and decrease toxic substrate accumulation Study results demonstrate lead compounds increase GCase protein levels, activity and co-localization in the lysosome, and decrease toxic substrate accumulation

Gain Therapeutics Presents Additional Confirmatory Data on its Gaucher Disease Program at the 2022 Glycolipid and Sphingolipid Biology Gordon Research Conference

$36.88 Million in cash as of December 31, 2021, provides runway into second half of 2023 and a strong cash position to transition the Company's lead program into clinical trials --- Compelling preclinical data presented on lead program GBA1 Parkinson's Disease at multiple scientific conferences supports transition to clinical stage company with FIH trial by year end ---  Entered into multi-target deal with Zentalis Pharmaceuticals to identify novel small molecules for oncology indications

Gain Therapeutics, Inc. Reports Full Year 2021 Financial Results and Business Update

Gain Therapeutics Inc (NASDAQ: GANX) has presented new preclinical data from its Parkinson's and Alzheimer's Disease programs.  These results were highlighted at the International Conference on Alzheimer's (AD) and Parkinson's Diseases (PD).

Gain Therapeutics Posts Encouraging Preclinical Data From Parkinson's, Alzheimer's Programs

- Oppenheimer 32 nd Annual Healthcare Conference -

Gain Therapeutics Announces Participation in Upcoming Investor and Scientific Conferences

BETHESDA, Md., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming and accelerating drug discovery with structurally targeted allosteric regulators identified with its proprietary computational discovery platform, today held its inaugural research and development day webinar.

Gain Therapeutics Outlines Key Objectives for 2022 Following its Inaugural R&D Day

Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to Drug the Undruggable Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to Drug the Undruggable

Gain Therapeutics Announces Additional Details on its February 4th Virtual R&D Day

BETHESDA, Md., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Chief Executive Officer Eric Richman, will participate in the H.C. Wainwright Bioconnect Conference and invites investors to participate via webcast. Please see additional details below:

Gain Therapeutics to Participate at the H.C. Wainwright Bioconnect Virtual Conference

BETHESDA, Md., Dec. 28, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced the grant of an option to purchase 200,000 shares of the Gain's common stock and of 200,000 restricted stock units of Gain's common stock to Matthias Alder, its Chief Operating Officer. These awards were approved by the Compensation Committee of Gain's Board of Directors and granted under the Gain Therapeutics, Inc. 2021 Inducement Equity Incentive Plan, with a grant date of December 23, 2021, as an inducement material to Mr. Alder to enter into an employment with Gain, in accordance with Nasdaq Listing Rule 5635(c)(4).

Gain Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Data Show Statistically Significant Increases in GALC Enzyme and Depletion of Toxic Substrate Psychosine Data Show Statistically Significant Increases in GALC Enzyme and Depletion of Toxic Substrate Psychosine

Gain Therapeutics Progresses Krabbe Disease Program and Provides Scientific Update

BETHESDA, Md., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Chief Executive Officer Eric Richman and Chief Scientific Officer Xavier Barril, Ph.D. of Gain Therapeutics, will present a corporate overview at the Imagine AI + Healthcare Investor Summit being hosted by Oppenheimer in partnership with the Alliance for AI in Healthcare (AAIH).

Gain Therapeutics to Participate at the Imagine AI + Healthcare Investor Summit

Brain-penetrant structurally targeted allosteric regulators for glucocerebrosidase (GCase) show promising in vivo pharmacological activity in Parkinson's Disease animal model Brain-penetrant structurally targeted allosteric regulators for glucocerebrosidase (GCase) show promising in vivo pharmacological activity in Parkinson's Disease animal model

Gain Therapeutics Presents Parkinson's Disease Preclinical Study Results at Society for Neuroscience Annual Meeting

Gain Therapeutics, Inc. (NASDAQ: GANX) shares were trading higher Wednesday after the company presented positive data on two of its lead compounds. What Happened: Bethesda, Maryland-based Gain announced positive data from a preclinical study evaluating two of its compounds, GT-02287 and GT-02329, which are being evaluated for the treatment of Gaucher and GBA1 Parkinson's disease.

Gain Therapeutics Stock Surges On Positive Preclinical Readout For Neurodegenerative Disease Drugs

Study results demonstrate first small molecule approach to significantly reduce phosphorylated and aggregated -synuclein and increase GCase protein levels  with transport to the lysosomes in iPSC dopaminergic neurons

News for Gain Therapeutics Stock (GANX)